Neuroblastoma (NB) is a pediatric cancer characterized by remarkable cell heterogeneity within the tumor nodules. Here, we demonstrate that the synthesis of a pol III-transcribed noncoding (nc) RNA (NDM29) strongly restricts NB development by promoting cell differentiation, a drop of malignancy processes, and a dramatic reduction of the tumor initiating cell (TIC) fraction in the NB cell population. Notably, the overexpression of NDM29 also confers to malignant NB cells an unpredicted susceptibility to the effects of antiblastic drugs used in NB therapy. Altogether, these results suggest the induction of NDM29 expression as possible treatment to increase cancer cells vulnerability to therapeutics and the measure of its synthesis in NB explants as prognostic factor of this cancer type.-Castelnuovo, M., Massone, S., Tasso, R., Fiorino, G., Gatti, M., Robello, M., Gatta, E., Berger, A., Strub, K., Florio, T., Dieci, G., Cancedda, R., Pagano, A. An Alu-like RNA promotes cell differentiation and reduces malignancy of human neuroblastoma cells. FASEB J. 24, 000 -000 (2010). www.fasebj.org
Neuroblastoma (NB) is a pediatric cancer, most often developing in children younger than 3 yr, that constitutes one of the most frequent cancers in infancy. Being a tumor specific of neural crest-derived cells, NB is characterized by a carcinogenic transformation of nerve cells from several areas of the body (for a comprehensive review, see ref. 1) .
A peculiar feature of NB is the remarkable heterogeneity of the cells that compose tumor nodules; in fact, they can derive from different neural crest lineages at variable stages of tumor differentiation and exhibit variable differentiation levels with significance for prognosis (2, 3) . Interestingly, a similar phenotypical diversity is also observed among (and even within) a large number of in vitro cultured NB cell lines, where 3 main phenotypes are often discernible: the cells that expand as poorly attached rounded aggregates with short neuritic processes (N type); the large flattened substrateadherent cells (S type); and the intermediate (I type), which are mildly adherent, show more marked stemlike traits, and are thought to originate both the S type as well as the N type (4) . Interestingly, several experimental proofs obtained both in vitro and in vivo support the hypothesis of the I-type NB cells as the true very malignant tumor initiating/stem-like cells, whereas the potential to originate tumors in vivo of the N-and the S-type cells is more modest (2) . This view has been recently strengthened by novel experimental evidence showing that in the tumor nodules, a small fraction of N-and/or S-type cells correlates with a poor prognosis and tumor recurrence (5) . Accordingly, other studies support the hypothesis that the phenotype of the NB cells that constitute the tumor nodules defines the malignant state of the nodules and exerts the most relevant influence on the prognosis, whereas the amplification status of Myc-N or its expression level is less predictive of the tumor fate (2) . In this context, according to the cancer stem cell hypothesis stating that the relative abundance of tumor initiating/stem-like cancer cells [hereafter referred to as tumor initiating cells (TICs)] in a nodule mass is of prognostic significance for its malignant potential, it is reasonable to hypothesize that the relative amount of I-type cells in NB masses might be possibly used to predict the evolution of tumor nodules. More importantly, the availability of chemicals potentially able to promote NB I-type cell differentiation would constitute an important advancement in the treatment of this cancer type. On the other hand, the identification of novel molecular markers suitable to unambiguously select and classify the diverse stages of differentiation of tumor masses (often histologically indistinguishable but with different prognosis and biological properties) would constitute a further significant hint to understand the high heterogeneity of NB cells.
In a recent work, we proposed a novel role in gene expression regulation of a set of small nuclear (sn)RNA-like transcripts whose synthesis is driven by RNA polymerase (pol) III-type 3 promoters (6) . These transcriptional units share a set of consensus sequences for regulatory elements, such as a TATA box, a proximal sequence element (PSE), and, often, a distal sequence element (DSE) that promote synergistically their synthesis (7) . The 29th transcription unit of our collection [hereafter referred to as neuroblastoma differentiation marker 29 (NDM29)] has a canonical Alu/7SL-derived sequence structure and maps in humans in an oncosuppressive portion of 11p15.3, a genomic region whose deletion has been shown to be involved in neuroblastoma development (8, 9) .
In this work, we demonstrate both in vitro and in vivo that the transcription of NDM29 RNA restricts NB cell malignancy, promoting the acquisition of a well-differentiated neuron-like phenotype, together with a dramatic reduction of TICs in the cell population. Notably, we also demonstrate that the expression of NDM29 RNA confers to refractory neuroblastoma cells the susceptibility to the antiblastics drugs, suggesting a chemical induction of NDM29 RNA expression as a possible treatment to NB and the measure of its synthesis as a marker of cancer prognosis for a better prediction of the fate of cancer nodules.
MATERIALS AND METHODS

Methylcellulose colony formation assay
Clonogenic assays were performed using a methylcellulose medium consisting of RPMI 1640 with 0.9% methylcellulose (Methocult H4100; StemCell Technologies, Vancouver, BC, Canada), 10% FBS, 100 U/ml penicillin/streptomycin, and 2 mM l-glutamine. Cells were plated at a density of 10 4 cells/ml in 1 ml volume of methylcellulose medium in humidified 24-well plates. For each assay, suspension cells were plated in triplicate. Colonies were counted between 7 and 9 d after plating.
Immunofluorescence detection
Cells were washed in PBS and fixed for 10 min in paraformaldehyde 4% in PBS (0.1 M, pH 7.4), then permeabilized with 0.25% Triton-X100 in PBS and blocked for 30 min in 3% BSA. Cells were then incubated for 16 h at 4°C in 0.5% BSA in PBS, with the primary antibody (rabbit polyclonal antiHuD 1:250; Santa Cruz Biotechnology, Santa Cruz, CA, USA). The next day, cells were incubated 45 min in 5% BSA/PBS with the secondary antibody (anti-rabbit rhodamine-TRITC, 1:100; Jackson ImmunoResearch, Bar Harbor, ME, USA). Cells were then incubated 5 min with DAPI. The immunolabeled cells were observed with the Axiovert 200M microscope (Zeiss, Jena, Germany) and captured at the same adjustments of laser intensity and photomultiplier sensitivity using Axio Vision software (Zeiss).
In vitro transcription
The in vitro transcription assays were carried out using a HeLa cell nuclear extract (10) . Transcription reactions were carried out in a final volume of 25 ml in the presence of 2 mg of template DNA and HeLa cell nuclear extract (100 mg) supplemented with 50 ng of recombinant human TBP. The standard transcription mix contained 5 mM creatine phosphate; 70 mM KCl; 5 mM MgCl 2 ; 20 mM Tris/HCl, pH 8; 1 mM DTT; 2 mg/ml ␣-amanitin; 0.5 mM CTP, ATP, and GTP; 25 mM/ 10 mCi [␣-32 P]UTP; 10 U SUPERase IN (Ambion, Austin, TX, USA); and 10% glycerol (v/v). The reactions were incubated for 1 h at 30°C. The products were phenol extracted, precipitated with ammonium acetate, gel-fractionated, and visualized by phosphorimaging using a Personal Molecular Imager FX (Bio-Rad, Hercules, CA, USA).
Primer extension reaction
For primer extension analysis, a double-scale transcription reaction was performed, without including radiolabeled UTP. The purified transcripts were resuspended in a final volume of 12 l in the presence of 0.5 mM dNTPs and 1 pmol of specific 5Ј-end-radiolabeled probe. The mixture was heated at 65°C for 5 min, and a mixture providing 50 mM Tris/HCl, pH 8; 75 mM KCl; 3 mM MgCl 2 ; 5 mM DTT; 10 U SUPERase IN; and 200 U Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA, USA) was added to a final volume of 20 l. The reactions were incubated for 1 h at 60°C and subsequently for 15 min at 70°C to inactivate the enzyme. The products were precipitated with ammonium acetate and gel-fractionated.
Nuclear and cytosolic fractionation
SKNBE2 cells from a 10-cm plate were resuspended in buffer A, containing 10 mM Tris-HCl, pH 7.5; 10 mM potassium chloride; 1.5 mM magnesium chloride; 1 mM dithiothreitol; AEBSF (Uptima, London, UK); peptide inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA); and RnaseOUT (Invitrogen). Cells were incubated on ice for 20 min, 0.25% Triton X-100 was added, and cells were resupended by pipetting for 10 min. Cells were centrifuged for 4 min at 3500 rpm, and the supernatant was kept as the cytoplasmic fraction. Buffer A was added once again, and the operation was repeated. The supernatant was added to the cytoplasmic fraction. Buffer B (20 mM, Tris-HCl, pH 7.5; 500 mM sodium chloride; 1.5 mM magnesium chloride; 1 mM dithiothreitol; 0.2 mM EDTA; proteinase inhibitors; and RnaseOUT) was added to the pellet. Cells were incubated for 10 min on ice and subjected to 3 passages into liquid nitrogen, followed by incubation at 37°C. Samples were centrifuged at maximum speed for 10 min, and the supernatant was kept as the nuclear fraction. After extraction with TRIzol, an equal fraction of nuclear and cytoplasmic extract was reverse transcribed using the Transcriptor high-fidelity cDNA synthesis kit (Roche Applied Science, Mannheim, Germany), following the manufacturer's instructions. Real-time PCR analysis of each sample was performed.
Cell adhesion assay
This protocol is adapted from McClay et al. (11) . After 36 h of siRNA treatment, cells were detached from the cell culture plate by trypsinization and plated at 1.5 ϫ 10 5 cells/well in a 24-well tissue culture plate; 3 h after cell plating, the multiwell plate was centrifuged twice in inverted position (well bottom placed up in a swing-out rotor) at 1000 rpm for 30 s. The cells still adherent to the wells were then processed in two different ways in independent experiments: viable cells were evidenced by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric method (12), or they were washed twice with PBS, fixed in 3.7% paraformaldehyde in PBS, and stained with methylene blue. After the staining, the cells were analyzed by digital imaging, and cells were counted.
Cell cycle analysis
The cell cycle was analyzed after 70/30% ethanol/water fixation permeabilization with 1% Nonidet P-40 (Sigma) and labeling with propidium iodide (PI; Sigma) (1, 2) . Samples were run on a FACSort cytofluorimeter (Becton Dickinson, Palo Alto, CA, USA), and cell cycle analysis was performed by the ModFit LT 3.0 computer program (Verity Software House, Topsham, ME, USA), identifying G 0 /G 1 and G 2/ M cells as cells with PI MFI of x or 2x, and cells in S phase as cells with PI of x Ͻ MFI Ͻ 2x (1, 2).
DNA sequencing
Plasmid constructs and real-time qPCR bands were sequenced by automated cycle sequencing using BigDye terminator, DNA sequencing kit, (Applied Biosystems) following manufacturer's instructions.
Detection of fast inactivation of K ؉ channels
In all of the experiments, membrane currents were measured with the standard whole-cell patch-clamp technique using an EPC-7 amplifier (List Medical, Darmstadt, Germany), as described previously (13) . Patch pipettes were prepared from borosilicate glass capillaries (type 1406129; Hilgenberg, Malsfeld, Germany) using a Model P-30 puller (Sutter Instruments, Novato, CA, USA). Membrane potential and ionic currents were measured in the standard whole-cell patch clamp configuration. Ionic currents were recorded with a Labmaster D/A, A/D converter driven by pClamp software (Axon Instruments, Burlingame, CA, USA). Analysis was performed with p-Clamp and Sigma Plot software (Jandel Scientific, Erkrath, Germany).
The standard external solution contained (in mM) 135 NaCl, 5.4 KCl, 1.8 CaCl 2 , 1 MgCl 2 , 5 HEPES, and 10 glucose; pH was adjusted to 7.4 using NaOH. The pipette filling (internal) solution contained (in mM) 142 KCl, 10 HEPES, 2 EGTA, 4 MgCl 2 , 3 ATP, and 300 nM tetrodotoxin; pH was adjusted to 7.3 with Tris base. All chemicals were purchased from Sigma-Aldrich. The external solution was applied to the cell bath by steady perfusion (Ϸ3 ml/min gravity flow). The potassium currents were elicited from a holding potential of Ϫ80 mV by depolarizing voltage pulses ranging from Ϫ40 to ϩ60 mV at 20-mV increments. The depolarizing voltage pulses of 200 ms duration were applied every 5 s. A best-fit exponential function was used to determine the time constant of the current inactivation. All recordings were performed at room temperature.
Proliferation assay
We tested proliferation of different cells transfected with different NDM29 constructs, plating 5 ϫ 10 5 cells/well in round-bottomed 96-well plates; cells were incubating for 48 h after transfection and pulsed with [ 3 H]-thymidine (3.0 Ci/10 l/well) (GE Healthcare, New York, NY) for the last 18 h. We harvested the cells and evaluated cell proliferation by counting the thymidine uptake. We calculated the average proliferation rate, measured as counts per minute (cpm), and sd for the triplicate wells of each sample.
Cell culture, transfection, and luciferase assay
Different cells lines were used: HeLa (grown in DMEM supplemented with 10% FBS) and SKNBE (grown in RPMI supplemented with 10% FBS). Cells were transfected using polyethylenimine (PEI; Sigma P3143) with pEGFP-N1 as control (hereafter referred to as pMock) or pEGFP-N1-NDM29 (hereafter referred to as NDM29). G418 (Geneticin; Invitrogen) was used in culture medium as mean of selection up to 1000 g/ml, until resistant clones were identified. After selection, the clones were preserved in 200 g/ml G-418 in standard culture conditions. The luciferase-based promoter activity assay was performed 48 h after transfection by firefly luciferase activity determination with the dual-luciferase reporter-assay system (Promega, Madison, WI, USA) according to the manufacturer's protocol. To specifically inhibit RNA polymerase III, ML-60218 (a cell-permeable cholobenzenesulfonamide; Calbiochem, San Diego, CA, USA) was added to the medium at the concentration of 20 M for 24 h before the assay.
Real-time quantitative RT-PCR analysis
Total RNAs were extracted from samples using TRIzol reagent (Invitrogen) according to the manufacturer's protocol and subjected to reverse transcription by Omniscript RT Kit (Qiagen, Valencia, CA, USA), following the manufacturer's instructions. The total RNA from samples was measured by real-time quantitative RT-PCR using PE ABI Prism@ 7700 Sequence Detection System (Perkin Elmer, Wellesley, MA, USA) and the SYBR Green method, following manufacturer's instructions. The sequences of forward and reverse primers were c-kit, forward 5Ј-GCAAGTCAGTGCT-GTCGGAA and reverse 5Ј-AAGATAGCTTGCTTTGGACACAGA-3Ј; mmp-9, forward 5Ј-CACTCGCGTGTACAGCCG-3Ј and reverse 5Ј-TCGAAGGGATACCCGTCTCC-3Ј; tyrosinase, forward 5Ј-GCCCAGCATCATTCTTCTTC-3Ј and reverse 5Ј-TTGCATAAA-GACTGATGGCTGT-3Ј; NF-68, forward 5Ј-CAAGGACGAGGT-GTCCGAG-3Ј and reverse 5Ј-CCCGGCATGCTTCGA-3Ј; U6, forward 5Ј-AATTGGAACGATACAGAGAAGATTAGC-3Ј and reverse 5Ј-TATGGAACGCTTCACGAATTTG-3Ј; and NDM29, forward 5Ј-GGCAGGCGGGTTCGTT-3Ј and reverse 5Ј-CCACGCCTGGCTAAGTTTTG-3Ј.
For endogenous control, the expression of glyceraldehyde 3 phosphate dehydrogenase (G3PDH) gene was examined. The sequences for human G3PDH primers were 5Ј-GAAGGTGAAG-GTCGGAGTC-3Ј and 5Ј-GAAGATGGTGATGGGATTTC-3Ј. The sequences for human 5s rRNA primers were 5Ј-TACGGCCATACCACCCTGAA-3Ј and 5Ј-GCGGTCTCCCATC-CAAGTAC-3Ј. The sequences for human 7SK RNA primers were 5Ј-AGGACCGGTCTTCGGTCAA-3Ј and 5Ј-TCATTTGGATGT-GTCTGCAGTCT-3Ј. The sequences for human c-Myc primers were 5Ј-CGTCTCCACACATCAGCATAA-3Ј and 5Ј-GACACTGTCCAACTTGACCCTCTT-3Ј. Relative transcript levels were determined from the relative standard curve constructed from stock cDNA dilutions and were divided by the target quantity of the calibrator, following manufacturer's instructions.
MTT assay
The effect of antitumoral drugs on neuroblastoma cell survival was evaluated using the MTT assay, a spectrophotometric measure of mitochondrial function, which represents an indirect index of cell number. It was performed measuring the reduction of MTT (Sigma-Aldrich) to purple formazan crystals by mitochondrial dehydrogenase. At 48 h after plat-3 AN ALU RNA RESTRICTS NEUROBLASTOMA MALIGNANCY ing, cells were exposed to the tested drugs for different times at 37°C. At the end of the treatment, the medium was removed, and cells were incubated for 1 h in MTT solution (2 mg/ml in PBS). After removing MTT, 500 l of DMSO was added to each well to dissolve the formazan crystals, and the absorbance was determined at 570-nm wavelength (14) .
NDM29 down-regulation
For NDM29 down-regulation, an engineered microRNA (miRNA-NDM29; 5Ј-TGCTGTTCAACAAGCAATAGCGTC-TAGTTTTGGCCACTGACTGACTAGACGCTTGCTTGTT-GAA-3Ј) was designed against the NDM29-transcribed sequence following the BLOCK-iT Pol II miR RNAi Expression Vector kit guidelines (Invitrogen) and cloned in the pCEG vector. Control experiments were performed using either pCEG alone or the pCMMP retroviral GFP vectors.
Statistical analysis
The Spearman's correlation coefficient (r) was used to evaluate the consistency between the established tumors formed in mice injected with mock, S2, and S1 cells and NDM29 expression.
RESULTS
NDM29 is a novel pol III-transcribed ncRNA
In search of novel human pol III type 3 transcription units, we found in the first intron of the Achaete ScuteLike homologue 3 gene (ASCL3; RefSeq: NC_000011.8), a combination of consensus sequences that potentially account for a functional pol III type 3 promoter. The potential transcription unit NDM29, (referred to as 29A in ref. 6 ) is endowed with the pol III type 3 regulatory elements upstream to the transcribed region and lacks the intragenic tRNA-like elements (box A and box B). The transcript comprises Alu sequences and unique sequences and might have been inserted into the genomic locus by retrotransposition (see Supplemental Fig. S1 for NDM29 RNA sequence and promoter features).
To test whether NDM29 RNA is a pol III transcription unit, we first verified its activity as a pol III template in vitro, using a HeLa cell nuclear extract. In vitro transcription of a plasmid-borne NDM29 construct containing the upstream PSE and TATA box, followed by the putative transcribed region (Fig. 1A) produced Ն2 specific RNAs of large size (Ͼ400 nt; Fig. 1B , lane 1). Such a pattern was difficult to interpret, presumably because of the lack of canonical pol III terminators in the NDM29 transcription unit (see below). To gain more precise information on the 5Ј end of in vitroproduced transcripts, we performed a primer extension analysis of the in vitro transcription products, which revealed that they initiated ϳ25 bp after the TATA-like element, as expected from type 3 promotors (Fig. 1C) . Since the in vitro transcription assays were performed in the presence of ␣-amanitin at a concentration able to block the transcription by pol II, these results suggested that NDM29 is specifically transcribed by pol III. The lack of an easily interpretable transcript pattern in Fig.  1A is likely due to the lack of a strong termination signal, as argued from the observation that the introduction of a strong terminator (a stretch of 9 T residues) within the transcribed region at a position ϳ130 bp downstream of the transcription start site produced an efficiently terminated ϳ130-nt transcript (data not shown).
To test the activity of NDM29 promoter in different cells and/or conditions, we fused ϳ600 bp of its type 3 promoter to a luciferase silencer hairpin (pSHAG-NDM29; hereafter referred to as pS-NDM29; see Supplemental Fig. S2 for the sequence of the hairpin). In this condition, if NDM29 promoter is active, the transcription of the hairpin drives the posttranscriptional silencing of a cotransfected luciferase cDNA and the decrease of its signal; on the contrary, an unaltered luminescent signal indicates that luciferase is not silenced because NDM29 promoter is not active.
As shown in Fig. 1D , we detected a significant decrease of luciferase emission in cells transfected with pS-NDM29 (Ϫ70%), 48 h after cotransfection of these constructs with a plasmid expressing luciferase (pGL3) in HeLa cells, demonstrating an efficient transcription of the hairpin driven by NDM29 promoter. As a positive control, a construct harboring the same luciferasesilencing hairpin under the control of a well-assessed type 3 promoter (H1, the RNA component of the RNase P ribonucleoparticle) led to a luminescence emission reduction of the 60% with respect to the negative control (a promoterless hairpin) that does not alter luciferase signal and to which all of the results were normalized. Since Alu RNAs are known to be synthesized specifically by primate cells, we also tested the possible primate specificity of transcription of NDM29, repeating the same experiment in murine NIH3T3 cells. Results showed that the emission of luciferase is not altered by either pS-NDM29, the promoterless construct (pS-Np) and the pGL3/pRL negative control constructs, indicating that NDM29 promoter is not readable by the murine NIH3T3 cells; on the contrary, under the same conditions, pS-U6 and pS-H1 constructs, harboring the luciferase-specific hairpin driven by U6 and H1 snRNAs promoter, respectively, are transcriptionally active (Fig. 1D) . Altogether, these data demonstrate that the bioinformatically predicted promoter of NDM29 drives efficient transcription of a downstream transcript in human cells and that this transcriptional activity is abolished in mouse NIH3T3 cells. Next, to further investigate the possible human-specific transcription of NDM29 promoter, and considering its high activity in human neuroblastoma cells, we repeated the same analysis in 3 mouse neuroblastoma cell lines. Results showed that NDM29 promoter is actively recognized in Neuro2A and NB41a3 and unrecognized in N1E-115 cell lines, demonstrating its ability to activate pol III transcription in specific mouse neural crest-derived cells (Fig. 1E) . Therefore, the above results demonstrate that NDM29 promoter is recognized in a cell type-rather then species-specific manner.
Next, to assess the pol III dependency of NDM29 RNA synthesis, we performed the same promoter activity assay in cells treated for 24 h with 20 M ML-60218, a cell-permeable indazolo-sulfonamide compound that displays a broad-spectrum inhibitory activity against pol III (15) . Figure 1F shows that when normalized to their untreated counterparts (characterized by an efficient luciferase-silencing activity in the absence of the inhibitor), the samples treated with ML-60218 exhibit a significantly increased luciferase signal, associating the decreased synthesis of this hairpin in ML-60218-treated samples to the inhibition of pol III activity. Next, we treated the cells with a pol II-specific inhibitor (␣-amanitin) for 30 h; as expected, this did not affect luciferase emission (Fig. 1F) . As a further control, the pol III-specific effect of ML-60218 was assessed, measuring the transcription rate of NDM29 and two wellassessed pol III-dependent ncRNAs (7SK and 5S rRNA) by real-time RT-PCR. As expected, in these experimental conditions, the synthesis of 5S rRNA (GeneID: 100169751), NDM29 RNA (see Supplemental Fig. S1 for NDM29 RNA features) and 7SK RNA (GeneID: 125050) is inhibited (up to 0.01Ϯ0.002, 0.7Ϯ0.08, and 0.3Ϯ0.02, respectively), whereas under the same conditions, the transcription of a pol II control gene (c-Myc, NCBI accession no. 002467) is not repressed Fig. S2 for the silencing hairpin sequence.) The promoter region encompasses the putative pol III type 3 regulatory regions (TATA box, PSE, and DSE). pGL3/pRL, negative control; pS-H1, pSHAG-H1 positive control; pS-U6, pShag-U6 positive control; pS-NDM29, pShag-NDM29; pS-Np, pShag-No promoter negative control. E) Promoter-activity transfection assay in murine N2a, NB41a3, and N1E-115 neuroblastoma cells. F) Promoter-activity transfection assay in cells treated (striped bars) or untreated (solid bars) with of 20 M ML-60218 cell-permeable pol III inhibitor or 10 mg/ml ␣-amanitin pol II-specific inhibitor. Results are reported as luciferase emission of treated vs. untreated samples. G, H) NDM29 (G) and 5S rRNA (H) expression in cells of different origin, as determined by real-time RT-PCR. P.F., primary skin fibroblasts; P.G., primary glioma cells. Insets: amplification product dissociation curves unambiguously distinguish the RNAs of interest by peaks at specific temperatures. I) Subcellular localization of NDM29 RNA as determined by RT-PCR analysis. Solid bars, cytoplasm; hatched bars, nucleus. Two well-established cytoplasmic (BC200) or nuclear (U6) RNAs are reported as controls (see also Supplemental Figs. S1 and S2).
(1.2Ϯ0.012) (Supplemental Fig. S2A ). Next, in order to test the possible effects of ␣-amanitin on NDM29 and/or luciferase synthesis, we measured the amounts of their transcripts in treated cells by real-time RT-PCR. Results confirmed that the treatment with ␣-amanitin does not inhibit the synthesis of NDM29, corroborating the above results. Conversely, this treatment reduces the amount of luciferase mRNAs in the cell by about half, although its enzymatic activity is not significantly affected (see above and Supplemental Fig. S2B) . These results clearly demonstrate that the inhibition of NDM29 promoter activity by ML-60218 observed under our experimental conditions is indeed due to the diminished transcriptional rate of pol III and does not affect the transcription by pol II.
To test whether NDM29 promoter is differentially active in cells of diverse origin, we measured the amount of endogenous NDM29 RNA in 6 different cell types by real-time RT-PCR. We found that NDM29 is particularly abundant in neuroblastoma cell lines (SHSY5Y and SKNBE2) and in a primary culture of human glioma (PG) cells, whereas HeLa, HEK293, and primary cultures of skin fibroblast (PF) cells express NDM29 at a very low level (Fig. 1G) . These results suggest that NDM29 RNA might play a preeminent role in cells of the nervous system rather than in epithelialderived cells. Next, to assess whether the specific expression of NDM29 in cells of the nervous system was due to a cell type-specific regulation of transcription or to a more general modulation of the activity of pol III machinery in these lineages, we measured the amount of the ubiquitously expressed pol III type 1 promoterdependent 5S rRNA in these samples. Results show that 5S rRNA is ubiquitously expressed in all the above cells and exhibit the highest level of synthesis in the highly proliferating HeLa cells, in accord with the view of a very active transcription by pol III in cancer cells that are in an active proliferation state (reviewed in ref. 16) (Fig. 1H) . These results indicate that NDM29 RNA is efficiently transcribed in neuroblastoma and PG cells, making these cell lines suitable for more detailed experiments on its function.
The subcellular localization of NDM29 was then determined by real-time RT-PCR, measuring the amount of NDM29 RNA in the cytosolic and in the nuclear fractions of SKNBE2 cells. We found 71% of NDM29 RNA in the cytosol and 29% in the nucleus. A well-characterized neuron-specific cytosolic RNA, BC200, was localized 85% in the cytosol and 15% in the nucleus. The nuclear RNA U6 was localized 70% in the nucleus and 30% in the cytosol (Fig. 1I) . These results suggested that NDM29 RNA may exert its biological function in the cytosol. Similar results were obtained using HeLa cell nuclear extracts, confirming the cytosolic localization of NDM29 (data not shown).
NDM29 expression leads to NB cell differentiation
The observation that cells displaying higher transcription rates of NDM29 are those having the highest population doubling (PD) time (such as SHSY5Y, SKNBE2, and PG cells), whereas highly proliferating cells (HeLa, HEK293, and PF) show very low-level NDM29 synthesis, prompted us to investigate a possible involvement of NDM29 RNA in cell cycle control. To this aim, we generated 3 plasmid constructs harboring different regions of NDM29 transcription unit to be transiently transfected in SKNBE2 and/or in HeLa cells: pNDM29, which harbors the whole NDM29 transcription unit; pNDM29-1, which includes the promoter region of NDM29 (containing an AluSg element) and lacks its transcribed portion; and pNDM29-2, which is composed of the NDM29 type 3 promoter (comprising the PSE and the TATA box) followed by the NDM29-transcribed portion ( Fig. 2A) . At 48 h after transfection, the proliferation rate of SKNBE2 cells was tested by [ 3 H]-thymidine incorporation assay. The plasmid constructs encompassing the transcribed portion of NDM29 transcription unit (pNDM29 and pNDM29-2) led to a marked decrease of cell proliferation (0.6Ϯ0.18 and 0.48Ϯ0.15 vs. pMock-transfected cells for pNDM29 and pNDM29-2, respectively), whereas cells transfected with the promoter region (pNDM29-1) exhibited a proliferation rate comparable to that of pMock-transfected cells (0.97Ϯ0.12). Similar results were obtained in HeLa cells, demonstrating that NDM29 expression inhibits proliferation in cells of different origin and thus suggesting that NDM29 may represent a general mechanism for the control of cell proliferation (Fig. 2B) .
Next, to quantitatively assess the correlation between the expression of NDM29 and cell cycle control, we generated 3 permanently transfected cell lines: mock-SKNBE2 (M) cells, transfected with pEGFP-N1 plasmid, which express NDM29 at its basal level; S2-SKNBE2 (S2) cells, which express a 2.2-fold increased level of NDM29 RNA; and S1-SKNBE (S1) cells, which express a 5.4-fold increased level of NDM29 RNA (Fig. 2C, D) ; and we measured cell PD by [ 3 H]-thymidine incorporation assay. We found that M cells duplicate every 30 h, whereas S2 and S1 cells exhibit an increased PD time of 39 and 48 h, respectively, demonstrating that the level of expression of NDM29 RNA correlates negatively with the cell proliferation rate and evidencing further that its variable synthesis drives to a proportional delay of the cell cycle (Fig. 2D) . Considering that, in principle, cell proliferation is alternative to cell differentiation, and bearing in mind that the highest level of expression of NDM29 was detected in the most differentiated NB cell line (SHSY5Y), we postulated that the NDM29-dependent inhibition of proliferation might be concomitant to the triggering of a differentiation process. To test this hypothesis, we measured the expression of matrix metalloprotease 9 (MMP9; NCBI accession no. NP_004985.2), a canonical marker of differentiation of NB cells in NDM29-overexpressing SKNBE2 cells. We found that besides the 2.2-fold increased expression of NDM29 RNA that leads to a PD time of 39 h, S2 cells exhibit a 3-fold increased expression of MMP9, whereas S1 cells, characterized by a 5.4-fold increased synthesis of NDM29 RNA that leads to a PD time of 48 h, overexpress MMP9 up to 75-fold with respect to the basal level detected in M cells (Fig. 2D) .
Considering that the phenotype observed in NDM29-overexpressing cells might be, in principle, independent of NDM29 expression but rather due to the selection of the cell lines, we tested for a direct correlation between NDM29 synthesis and the cell differentiation features by different approaches. First, we characterized 3 additional permanently transfected clones (hereafter referred to as M2, for a second cell line transfected with the empty vector, and S6 and S7, which were transfected with NDM29), measuring by real-time RT-PCR NDM29 and MMP9 expression and the corresponding changes of PD. As expected, we found that both the expression of MMP9 and the PD correlate with the expression of NDM29. Therefore, these data further support the functional correlation between the synthesis of the ncRNA and the acquisition of a differentiated phenotype, as previously observed in S1 and S2 clones (Fig. 2E ). Next, we tested the possible effects of NDM29 down-regulation, taking advantage of an NDM29-specific microRNA (miRNA-NDM29). To test the efficiency of the silencing procedure, SKNBE2 wild-type cells were cotransfected with a construct expressing NDM29 and miRNA-NDM29 (or a scrambled negative miRNA control). We found that 48 h after transfection with miRNA-NDM29, the expression of NDM29 is only barely detectable, whereas the PD time of the silenced cells decreases to 25 h (9% of reduction) (Fig. 2F) . Therefore, these results confirm after transient transfection (thus at a lower extent, since transfected cells were not positively selected) that the changes of cell cycle duration observed in NDM29 permanently transfected cells S1 and S2 are strictly dependent on NDM29 synthesis. Last, we transfected M, S2, and S1 cells with the same constructs and measured the expression of MMP9. Results showed that in all of the cell types, the inhibition of NDM29 expression is accompanied by a decrease of MMP9 synthesis in all the cell clones, confirming again the unambiguous correlation between the expression of the ncRNA and the pheno- 7 AN ALU RNA RESTRICTS NEUROBLASTOMA MALIGNANCY type described above (Fig. 2G) . Altogether, these results demonstrate that moderate overexpression of NDM29 RNA brings to a delayed cell cycle and to an equivalently moderate commitment to differentiate, whereas a more robust NDM29 synthesis further enhances cell cycle duration, promoting a higher level of differentiation.
Because the above results also suggest possible changes associated with the cell cycle regulation, we tested the distribution of the 3 cell populations by PI-based FACS analysis. This experiment showed that alterations of specific cell cycle phases are associated with NDM29 expression. In detail, we found that the population of slowcycling S1 cells is characterized by a low fraction of cells in G 0 -G 1 , compatible with their delayed M phase exit, and an increased fraction of cells in S phase, compatible with a prolonged/delayed DNA synthesis (Fig. 2H) . In this experiment, the S2 cell population, which is characterized by an intermediate value of cell cycle duration, exhibited a distribution of cells among cell cycle phases between those of S1 and M cells. Altogether, this information is consistent with the slowdown of the cell cycle detected in NDM29-overexpressing cells and suggest a further detailed analysis of the effects of NDM29 synthesis on the different phases of the cell cycle.
The analysis of these SKNBE2 cells also showed clear morphological variations proportional to the synthesis of NDM29 RNA: S1 cells are ϳ5-fold bigger than their M counterparts and form an abundant network of neuritic processes characteristic of a neuron-like phenotype, whereas S2 cells exhibit a moderate amount of relatively short neuritic processes and a less differentiated cell shape (Fig. 3A) . Immunofluorescence analysis of a RNA-binding protein specifically expressed by neurons (HuD, Hu antigen D, accession no. 068771.2) showed 95.2 and 80.6% positive cells in S1 and S2 populations, respectively, whereas only 15.7% of M cells were positive for this marker; considering that the expression of HuD is associated with neuron plasticity during brain development (17), these results further define the neuron-like phenotype promoted by the overexpression of NDM29 RNA in NB cells (Fig. 3B) . Next, to better understand these data, we estimated the fraction of cells that overexpress NDM29 ncRNA at a level sufficient to induce an expression level of HuD antigen detectable with immunofluorescence. To this aim, we selected 8 subclones from each cell line by limiting dilutions and measured the expression level of NDM29 by real-time RT-PCR. We found that, considering the averaged expression of the clones of the M cell line (0.5 after normalization to GAPDH housekeeping gene) as a threshold level of endogenous expression of NDM29 [only 2 clones of M cells (25%) overexpressed NDM29 at a level significantly higher with respect to the average], 8 of 8 S1 cells (100%) expressed a highest level of NDM29. In the same experiment, we also found that 6 of 8 S2 cells (75%) exhibited a level of NDM29 transcription Ͼ0.5 with respect to GAPDH, whereas the remaining clones (25%) synthesized a lower level of NDM29 (Fig. 3C) . Altogether, these results confirm the data obtained by the immunostaining of HuD as the fraction of cells overexpressing the ncRNA at a level Ͼ0.5 in the cell populations is compatible with the fraction of cells positive to HuD in the immunofluorescent analysis. In addition, realtime RT-PCR analysis of the expression of neurofilament 68 (RefSeq NP_006149.2; a marker of NB N-type cells), tyrosinase (RefSeq NP_000363.1; characteristic of the S-type neuroblastoma cells), and c-kit (RefSeq NP_000213.1; a well-assessed marker of the I-type neuroblastoma stem-like cells) confirmed that the neuron-like phenotype of SKNBE2 cells is tightly proportional to the expression level of NDM29 RNA. Since its synthesis leads to the proportional upregulation of neurofilament 68 and to the concomitant down-regulation of c-kit (a well-assessed marker of TICs), these results indicate a possibly decreased stemness potential of NDM29-overexpressing cells (Fig. 3D) .
To confirm the acquisition of neuron-like features in NDM29-overexpressing SKNBE2 cells, we tested their excitatory properties by patch clamp, measuring the A-type voltage-dependent current of potassium channels. Figure 3D shows the outward potassium current elicited in M and in S1 cells by depolarization steps from Ϫ80 mV holding potential. The inactivation time course of this current could be described by a single exponential curve detectable in NDM29-transfected cells and absent in pMock cells (Fig. 3E) . This experiment demonstrates that the differentiation process driven by NDM29 RNA involves the ultimate acquirement of the fast inactivation properties of the voltagedependent potassium channels, promoting the activation of their transient component of the A-type current. Therefore, considering that this phenomenon is a relevant component of the excitatory properties of functional synapses, we conclude that the synthesis of NDM29 confers to NB cells a well-differentiated phenotype with excitatory properties of cells with functional synapses.
NDM29-overexpressing cancer cells acquire an anchorage-dependent growth
Besides the overexpression of differentiation markers and the strong inhibition of c-kit expression detected in S1 cells, we also observed a strong increase of the adherence to the substrate consequent to NDM29 overexpression. To determine quantitatively the increase in anchorage-dependent growth, we seeded S1, S2, and M cells in glass chambers slides, where SKNBE2 cells do not adhere efficiently under normal conditions. After 24 h of culture, cell samples were stained with DAPI, and the average number of nuclei detected in 10 randomly chosen microscope fields was determined for each cell line. As shown in Fig. 4A , the expression of NDM29 RNA leads to a proportional increase of the cell adhesion capacity of SKNBE2 cells. To confirm the change in anchorage-dependent growth, we tested cell adhesion of S1, S2, and M cells on different substrates. Cells were seeded on fibronectin-and laminin-coated or, as negative control, uncoated dishes. After 24 h, the plates were centrifuged upside down and subsequently stained with methylene blue. In parallel experiments, cell adhesion capacity was determined by the MTT assay. Under all conditions, the number of adherent cells was propor- tional to the expression level of NDM29, corroborating a direct correlation between the two (Fig. 4B, D) .
NDM29 overexpression restricts neuroblastoma malignancy both in vitro and in vivo
Since the anchorage-dependent growth and the inhibition of c-kit expression acquired by NDM29-overexpressing SKNBE2 cells suggest a significant reduction of NB cell malignant potential, we investigated the effects of NDM29 RNA expression on tumor formation capacity. First, we tested the clonogenicity of M, S2, and S1 cells in methylcellulose. At 7 d after cell seeding, the average number of colonies per microscope field (as normalized to that of M cells) was 0.8 Ϯ 0.3 and 0.23 Ϯ 0.1% in S2 and S1 cells, respectively, demonstrating that the decreased clonogenicity of SKNBE2 permanently transfected lineages is strictly proportional to the expression level of NDM29 (Fig. 5A) .
To assess whether an increased expression of NDM29 might prevent tumor formation in vivo, we injected subcutaneously M, S2, and S1 cells (5ϫ10 6 cells/ mouse) in a first pool of 9 NOD-SCID mice and evaluated possible changes in the tumor formation frequency. At 64 d after the injection, 3 of 3 (100%) of the M-injected mice, 2 of 3 (66%) of the S2-injected mice, and 1 of 3 (33%) of the S1-injected mice developed tumor masses ranging from 12 to 14 g, whereas no traces of tumor formation were detected in the correspondent areas of negative mice. Therefore, this result suggested that in vivo, tumor formation capacity of NB cells is inversely correlated with the expression of NDM29 RNA. To verify this hypothesis, we injected subcutaneously a second pool of NOD-SCID mice (nϭ30) with 1 ϫ 10 6 cells/mouse. At 64 d after the injection, 6 of 10 (60%) of the M-injected mice, 5 of 10 (50%) of the S2-injected mice, and 2 of 10 (20%) of the S1-injected mice developed a tumor mass, confirming that the growth of NB nodules in vivo is efficiently antagonized by the expression of NDM29 RNA (Fig.  5B) . Notably, considering that the rate of tumor formation by a cancer cell population when injected in experimental animals is a quantitative measure of the fraction of TICs in the original cell population, these data demonstrate that the expression of NDM29 RNA prevents malignancy and promotes a cell differentiation process that also involves the TIC fraction of the cell population.
Next, to assess whether NDM29 expression also affects the differentiation stage of the tumor (as already observed in vitro), we measured by real-time RT-PCR the expression level of specific markers of NB cell differentiation (neurofilament 68, tyrosinase, MMP9) and of the self-renewal capacity (c-kit) in the nodules originated in vivo by the 3 different cell lines. First, we confirmed that the expression of NDM29 RNA is higher in S1-derived malignancies than in those originated by S2 and M cells. In addition, the increased expression of MMP9 and neurofilament 68, together with a slight decrease of the expression of c-kit in nodules derived by NDM29-overexpressing cells, demonstrates that the differentiation stage of the newly generated tumor masses is proportional to the expression level of NDM29 RNA in the cell population originally injected (Fig. 5C ). In accord with their molecular characterization, the analysis of the hematoxylin-and-eosin-stained tumor sections showed that the nodules formed by M cells (and, although to a lesser extent, by S2 cells) maintain the small cancer cell structure typical of human neuroblastoma, whereas the nodules formed by S1 cells exhibit a very different morphology characterized by well-oriented, large, fiberlike cells. Therefore, since the immunohistochemical staining with ␣-anti-GFP confirmed the human origin of the cells that compose the nodules (Supplemental Fig.  S3 ), these data demonstrate that in vivo, SKNBE2 cells form tumors at variable stages of differentiation according to their expression of NDM29 (Fig. 5D) . These results were statistically validated using Spearman's correlation coefficient, which confirmed the totally inverse relationship existing between the in vivo tumor formation and the expression of NDM29 (rϭϪ1).
Altogether, these data demonstrate that the expression of NDM29 RNA quantitatively influences tumor formation capacity of NB cells, supervising the differentiation stage of tumor masses; this phenomenon may account for the marked heterogeneity observed among and within human neuroblastomas and suggests a possible detection of NDM29 differential expression in NB tumor masses as a prognostic marker of their differentiation stage.
Last, to further demonstrate the quantitative correlation of NDM29 RNA expression with the differentiation of tumor nodules and, as a consequence, its inverse correlation with the malignancy and the aggressive behavior of tumor cells, we measured the expression of NDM29 and of the differentiation markers used above in a series of tumors and cell lines progressively enriched in their TIC fraction. To this aim, we repeated two cycles of S1 cell line injection/tumor formation/ cell line derivation in NOD-SCID mice and analyzed their differentiation stage. The progressive enrichment in TICs (as demonstrated by the onward increase of c-kit expression, tumor formation frequency, and cell clonogenicity in methylcellulose, and the concomitant marked reduction of the expression of the neuroblastoma differentiation marker MMP9) is accompanied by a proportional decrease of NDM29 RNA expression, demonstrating again that its amount in tumor nodules is inversely related to the fraction of TICs in the cell population that compose the nodules. Accordingly, the analysis of hematoxylin-and-eosin-stained tumor sections evidenced a progressive reacquirement of the small cells cancer phenotype typical of human neuroblastoma (see Supplemental Fig. S4 for a detailed description of the experiment). A repetition of this experiment was then performed starting from the partially differentiated S2 cells; again, the results confirmed that the expression of NDM29 is inversely related to the TIC enrichment in the cell population composing the nodules (see Supplemental Fig. S4) .
Therefore, besides the direct correlation between NDM29 expression and NB cell differentiation, these experiments also demonstrate in vivo that NB nodules at different maturation stages and with variable malignant potential can be formed, depending solely on the expression level of NDM29 ncRNA.
NDM29 overexpression forces NB cells to antiblastic susceptibility
The recent view of the cancer stem cell theory states that tumor-initiating, stem-like cells are at the origin of cancer relapses since they are refractory to chemotherapeutic drugs. These cells exhibit an undifferentiated phenotype and prevent the intracellular accumulation of drugs by the activation of multidrug resistance (MDR) detoxification pumps (18) . Since our experiments demonstrated that NDM29-driven differentiation converts tumor cells into a fiber-like poorly malignant phenotype, we speculated that the overexpression of NDM29 RNA might also increase the susceptibility to antiblastic treatments by the possible down-regulation of MDR expression. Thus, we assayed the response of S1, S2, and M cell lines to cytotoxic drugs, such as doxorubicin, cis-platinum, and imatinib-mesylate. The concentrations for treatment were chosen in preliminary dose-response experiments, as those close to calculated EC 50 values. S1, S2, and M cell lines (10 5 cells/well) were treated with cis-platinum (5 M), doxorubicin (0.5 M), and imatinib mesylate (50 M) for 1-7 d, unless cell death occurred earlier. We used the MTT assay to test the potential antiproliferative and cytotoxic effects of these drugs. cis-platinum slowed down the proliferation rate to a similar extent in all cell lines during the first 4 d of treatment. After 5 d, a significant cytotoxic effect was observed only for S1 cells, as compared to S2 and M cells, which resulted in death of almost all cells after 7 d of treatment. Similar results were obtained in experiments with doxorubicin. Cell proliferation was inhibited in S1 and S2 cells after the second day of treatment, and almost all cells were killed after 5 d. In contrast, M cells continued to grow, albeit at a slower rate, up to the fourth day of treatment, after which cells died. All cell lines showed the same response to the imatinib-mesylate treatment showing an induction of cell toxicity completely superimposable, independent by the expression of NDM29 (Fig. 6A-C) . To exclude a clonal effect in the different responses to drugs, we re-peated the same experiments using the other transfected cell lines previously characterized (see Fig.  2E ). As shown in the insets to Fig. 6A -C, a clear sensitization to both doxorubicin and cis-platinum cytotoxicity was observed in the cell lines overexpressing NDM29 (S6 and S7), as compared to the mock transfected cells (M2). Conversely M2, S6, and S7 cell lines showed similar response to imatinibmesylate, thus confirming the results obtained using M, S1, and S2 cells.
Next, to assess whether this different susceptibility has to be ascribed to the lack of detoxification potential, we measured the expression level of multidrug resistance 1 (MDR1; with which the efflux of cisplatinum and doxorubicin has been associated) (19) in the 3 cell lines by real-time RT-PCR. As shown in Fig.  6D , the expression of NDM29 leads to a strong inhibition of MDR1 synthesis. Interestingly, these results may explain the reduced resistance of S1 cells to both cis-platinum and doxorubicin, since the lower expression of MDR1 may prevent the efflux of the drugs, causing their intracellular accumulation and cell toxicity (Fig. 6A, B) . Conversely, imatinib-mesylate that it is not a target of MDR1 activity, persists in all the cell lines (Fig. 6C) . To confirm further that MDR1 inhibition is strictly dependent on NDM29 expression, we measured the expression of MDR1 RNA in S1 and M cells transfected with miRNA-NDM29. We found that MDR1 expression is increased in NDM29-silenced cells, thus confirming again that the enhanced susceptibility to , and imatinib-mesylate (C) effects on SKNBE2 cell survival. SKNBE2 cells constitutively expressing the mock plasmid (M2) or low (S2) or high (S1) levels of NDM29 ncRNA were treated with the drugs for different times, and cell survival was evaluated every day. S1 cells showed a higher susceptibility to cis-platinum and doxorubicin cytotoxicity than M2 transfected cells; S2 cells showed an intermediate phenotype, being more resistant than S1 in the presence of cis-platinum; but a comparable level of cell toxicity was observed in S1 and S2 when cells were treated with doxorubicin. On the contrary, the different levels of NDM29 expression did not modify the responsivity to imatinib-mesylate. Time points in boxes indicate a value of P Ͻ 0. antiblastic drugs observed in cells that overexpress NDM29 is dependent on the inhibition of the synthesis of MDR1 RNA (insets in Fig. 6D) . Therefore, these results demonstrate that the pharmacological induction of NDM29 expression might be a suitable therapy to be flanked to antitumoral drugs in order to extend their effect to the stem-like compartment.
DISCUSSION
In the past few years, it has been demonstrated that fully proliferating cancer cells exhibit a very active transcriptional activity of pol III to sustain their need of a vigorous protein synthesis, whereas their nonmalignant counterparts are characterized by a less dynamic pol III complex (15, 20) . In contrast, we here report the biological role of NDM29, a novel snRNA-like transcription unit that maps in the intron 1 of the ASCL3 gene, whose pol III-dependent transcriptional activity is inversely related to cell proliferation. Indeed, NDM29 synthesis is strongly increased in differentiating cells, where it leads to a slowdown of the cell cycle, and markedly reduced in malignant highly proliferating cells. Such an expression behavior is in sharp contrast with typical expression profiles of pol III-synthesized RNAs. Class III genes are generally characterized by strong basal promoters, supporting high levels of transcription, which undergo further increase in cancer cells, such as HeLa cells, due to deregulation of basal transcription factors. With this respect, it is tempting to speculate that NDM29 differential transcription might somehow be related to the recently reported existence of two isoforms of human RNA polymerase III, one of which seems to be restricted to undifferentiated ES cells and tumor cells (21) . In any case, the gene-and stage-specific regulation of pol III transcription, whose existence is strongly suggested by our data, provides an additional level of control over cancer development by synthesizing molecules necessary to sustain and/or restrict tumor growth. The subcellular localization of NDM29 RNA in the cytosol suggests that it may play a role in controlling the expression of specific mRNAs at the post-transcriptional level, most likely by regulating their translation and/or stability.
In this work, we first demonstrate in vitro that NDM29 plays a critical role in the balance between cell proliferation and differentiation; its stable overexpression drives malignant SKNBE2 cells to differentiate and to develop neuron-like traits such as neuron-like morphology endowed with a well-distinguishable network of neuritic processes; very low proliferation rate; excitatory properties typically associated with functional synapses; inhibition of the synthesis of c-kit, a well-known marker of stemness; anchorage-dependent growth; and expression of specific markers of neurons. Hence, the overexpression of NDM29 in NB cells is accompanied by the proportional lack of stem cell traits and by the simultaneous gain of those characteristics associated with nonmalignant cells, suggesting a possible use of NDM29 up-regulation to prevent cancer.
Besides the evidence obtained in vitro, our experiments also demonstrate that the overexpression of NDM29 actively prevents NB cell malignancy in vivo; indeed, the number of tumor nodules developed by mice injected with SKNBE2 cells is dramatically reduced by the overexpression of NDM29 RNA, which promotes a significant decrease of the fraction of cells with tumor-initiating/stem-like properties. Notably, we found that NB cells at a subterminal differentiation stage are still able to proliferate and generate tumors in NOD-SCID mice, although at a very low frequency and displaying peculiar histological features. Indeed, nodules derived from cells that express NDM29 at the basal level maintain their small cell structure, whereas those derived from NDM29-overexpressing cells lack the typical morphology of small cells cancer and gain a smooth muscle-like structure. These more differentiated tumor masses are composed by large cells with very low clonogenicity in nonadherent conditions and have a strongly reduced malignant potential. In our view, these differences are of particular interest, as they seem to recapitulate the high heterogeneity observed among and within human neuroblastomas, where the frequency and the distribution of different cell types are thought to account for the variability of tumor prognosis. In this context, the fact that the expression of NDM29 RNA reflects the differentiation stage of the nodules might help to better understand NB heterogeneity, suggesting the determination of its transcription level in tumor masses to predict their malignant potential and, possibly, to select the most appropriate therapy.
Besides the possible use of NDM29 as prognostic factor, the pharmacological induction of its expression might be also relevant for NB therapies due to the capacity of NDM29 ncRNA to render malignant NB cells more vulnerable to anticancer drugs. Indeed, after a first period of intracellular accumulation, NDM29-overexpressing cells die at a dosage of cis-platinum at which cells that express NDM29 RNA at its basal level are still viable. As NDM29-overexpressing cells proliferate slowly, they are expected to be more refractory to the action of antimitotic cytostatic drugs, such as cisplatinum and doxorubicin. On the contrary, our results clearly show that the expression of NDM29 RNA makes cells more vulnerable to these chemicals as its overexpression inhibits MDR1 expression, a cell surface detoxification pump, whose synthesis is at the base of the chemoresistance of TICs and/or cells with stem-like features. Therefore, our results show that a possible pharmacological treatment that stimulates the expression of NDM29 RNA in cancer nodules might constitute the starting point for a novel therapy that flanks the more traditional antiblastic treatments. As a matter of fact, the results reported here show that the expression of NDM29 RNA exerts its effects also on those slowly proliferating TICs that are refractory to the antitumor therapy. Thus, a treatment inducing NDM29 expression in cancer nodules might be used in synergy with the antiblastic therapy to render those elusive cells that are thought to provoke tumor relapse more vulnerable to the anticancer drugs. Nucleotide sequence of NDM29 transcription unit. The functional elements of the promoter are reported in bold and underlined. The transcribed portion is in italic. 
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